Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study - Kuzmanovszki, Daniella; Kiss, Norbert; Tóth, Béla; Kerner, Tünde; Tóth, Veronika; Szakonyi, József; Lőrincz, Kende; Hársing, Judit; Imrédi, Eleonóra; Pfund, Alexa; Szabó, Ákos; Brodszky, Valentin; et al. (Biomedicines, 2022)
Keywords: advanced melanoma; adverse event; Adverse events; anti-PD-1 monotherapy; Antibodies; Clinical outcomes; Clinical trials; Cytotoxicity; Data collection; Disease; Drug dosages; Electronic health records; immune checkpoint inhibitor; Immune checkpoint inhibitors; Ligands; Lymphocytes; Melanoma; Metastasis; Mutation; nivolumab; Observational studies; Patients; PD-1 protein; Pembrolizumab; Survival; Toxicity; Hungary